Table 4.
Factors associated with viral suppression.
| Variables | OR (95% CI) | P value* | aOR (95% CI) | P value* |
|---|---|---|---|---|
| Gender | ||||
| Female | 1 | 1 | ||
| Male | 0.65 (0.56–0.75) | <.0001 | 0.69 (0.60–0.81) | <.0001 |
| Age categories, N (%) | ||||
| 0–10 | 1 | 1 | ||
| 11–19. | 1.57 (1.05–2.36) | .028 | 1.28 (0.84–1.94) | .242 |
| ≥20 | 5.39 (4.05–7.16) | <.0001 | 3.72 (2.76–5.02) | <.0001 |
| ART combination | ||||
| TDF + 3TC + DTG | 1 | <.0001 | 1 | <.0001 |
| Other ART | 0.42 (0.36–0.48) | 0.47 (0.40–0.55) | ||
| ART Duration (mo) | ||||
| ≤24 | 1 | .46 | 1 | .024 |
| ≥25 | 0.78 (0.62–0.99) | 0.76 (0.59–0.96) | ||
Other ART: ARV [ABC + 3TC + EFV (n = 13), ABC + 3TC + NVP (n = 2), AZT + 3TC + EFV (n = 36), AZT + 3TC + NVP (n = 14), TDF + 3TC + NVP (n = 51), TDF + 3TC + EFV (1511)], Lopinavir based (n = 173) and atazanavir based (n = 117).
3TC = lamivudine, ART = antiretroviral therapy, aOR = adjusted odds ratio, CI = confidence interval, DTG = dolutegravir, OR = odds ratio, TDF = tenofovir disoproxil fumarate.
*
P value for virological success at < 1000 copies/M.